ERBB-2 overexpression confers PI 3 ′ kinase-dependent invasion capacity on human mammary epithelial cells by Ignatoski, K M Woods et al.
Amplification and overexpression of genes that regulate growth
and differentiation of normal cells is a common mechanism for
oncogene activation in human solid cancers. Among the onco-
genes known to be amplified and overexpressed in human breast
cancer (HBC) are ERBB-2 (Kraus et al, 1987; Slamon et al, 1987;
Berger et al, 1988; Guerin et al, 1989) (also known as HER-2/neu),
C-MYC (Bonilla et al, 1988; Borg et al, 1992; Watson et al, 1993),
CCDN1 (Gillet et al, 1994), FGFR 1, 2 and 4 (Luqmani et al,
1992; Jaakkola et al, 1993; Jacquemier et al, 1994), as well as
other less well characterized genes (Bieche et al, 1996; Anzick et
al, 1997; Sen et al, 1997). In addition to gene amplification, HBC
cells often acquire other genetic alterations that may play a role in
altered phenotypes expressed by cancer cells. And, while it is
often possible to determine the signalling pathways activated as a
result of gene amplification, it is much more difficult to discern the
role of a specific genetic change in the expression of altered
growth phenotypes exhibited by breast cancer cells.
Previously, we demonstrated that HBC cells with an amplifica-
tion of ERBB-2 express high levels of constitutively activated
p185ERBB-2 and exhibit varying degrees of growth factor indepen-
dence in vitro that is directly related to the level of overexpression
of the gene (Ram et al, 1996). More recently, we have been able to
recapitulate the growth factor independence phenotype in immor-
talized human mammary epithelial (HME) cells by overexpressing
ERBB-2 to levels equivalent to that expressed by breast cancer
cells, indicating that ERBB-2 itself can drive factor independent
growth when expressed to high enough levels (Woods Ignatoski et
al, 1999). In the present studies, we investigated the role of ERBB-
2 overexpression in the acquisition of other altered phenotypes
exhibited by breast cancer cells. We found that high level overex-
pression of ERBB-2 in the immortalized HME cell line H16N2
results, not only in the acquisition of anchorage-independent
growth capacity, but also in the ability to invade naturally occur-
ring basement membranes in a manner similar to breast cancer
cells. The ability of ERBB-2 to induce invasion is linked to its
ability to activate PI 3¢-kinase, involves down-regulation of a4b1
integrins, and may involve signalling from focal adhesion kinase,
which is associated with ERBB-2 in the overexpressing cells.
Thus, when expressed to very high levels, ERBB-2 becomes asso-
ciated with signalling complexes not detectable in normal cells,
and is directly involved in the acquisition of a number of pheno-
types characteristic of transformed cells.
MATERIALS AND METHODS
Cell culture
The base medium for H16N2-PTP, H16N2-ERBB2 and SUM-
190PT cells was Ham’s F12 media supplemented with 0.1% bovine
serum albumin, 0.5 mg ml–1 fungizone, 5 mg ml–1 gentamycin, 5 mM
ethanolamine, 10 mM HEPES, 5 mg ml–1 transferrin, 10 mM T3, 50
mM selenium and 1 mg ml–1 hydrocortisone. SUM-190PT cell
medium was further supplemented with 5 mg ml–1 insulin, and
H16N2-PTP cell medium was further supplemented with 10 ng
ml–1 epidermal growth factor (EGF). The medium for SUM-52PE,
SUM-149PT, and SUM-225CWN was Ham’s F12 supplemented
with 5% fetal bovine serum (FBS), 0.5 mg ml–1 fungizone, 5 mg
ml–1 gentamycin and 5 mg ml–1 insulin and further supplemented
with 1 mg ml–1 hydrocortisone. SkBr3 cells were grown in
Dulbecco’s modified Eagles medium (DMEM) supplemented with
10% FBS, 0.5 mg ml–1 fungizone and 5 mg ml–1 gentamycin. Cells
infected with retroviral expression vectors were selected in 100 mg
ml–1 geneticin (G418) for 2 weeks. All cell culture reagents were
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obtained from Sigma Chemical Co. (St Louis, MO, USA). Detailed
descriptions of all of the SUM cell lines can be found at
http://p53.cancer.med.umich.edu/clines/clines.html on the world-
wide web.
Retrovirus construction
pTPerbB-2 retrovirus construction was previously described
(Harris et al, 1998; Woods Ignatoski et al, 1999). pTPPTEN(wt)
and pTPPTEN (C124S) were constructed by excising the FLAG-
tagged PTEN genes from FLAG-PTEN/CMV5 (Maehama and
Dixon, 1998) with EcoRI and BamHI. The ends of each PTEN gene
were blunted and ligated into pTP 2000 which was digested with
XhoI and blunt ended. Five micrograms of DNA were transfected
into fNX-A cells by Ca2PO4 precipitation and virus was collected
48 h after transfection. Cells were infected with the appropriate
virus and selected in 100 mg ml–1 gentamycin for 2 weeks. Because
erbB-2 overexpressing cells already contained a construct that was
G418-resistant, we tested the quality of infectious pTPPTEN virus
by infecting non-G418-resistant MCF-10A cells and selecting in
100 mg ml–1 gentamycin for 2 weeks. Each pTPPTEN virus
infected approximately 75% of the MCF-10A cells.
Soft agar assays
Six-well dishes were coated with a 1:1 mix of the appropriate 2 ´
medium for the cell line being studied and 1% Bactoagar. Cells
were plated at 1 ´ 103, 1 ´ 104 and 1 ´ 105 cells per well in a
mixture of appropriate medium and 0.3% Bactoagar. Cells were
fed 3 times per week for 3 weeks, stained with 500 mg ml–1 P=Rho
iodonitrotetrazolium violet (Catalog no. I-8377, Sigma Chemical
Co., St Louis, MO, USA) overnight and photographed. Each cell
line was plated in duplicate in three separate dilutions. The experi-
ment was repeated three times.
FAK immunoprecipitations and protein blots
Cells were lysed in a buffer containing 20 mM Tris–HCl, pH 8.0,
137 mM sodium chloride (NaCl), 1% NP-40, 10% glycerol, 1 mM
Na3VO 4, 1 mM phenylmethyl sulphoxide (PMSF), 1% aprotinin,
20 mg ml–1 leupeptin. Protein concentrations were equalized to 
100 mg for whole cell lysates or to 1 mg for immunoprecipitations
using the Løwry method (Bradford, 1976). For whole cell lysates,
Laemmli sample buffer (Sambrook et al, 1989) was added and the
samples were boiled. For immunoprecipitations, 1 mg of a-FAK
antibody (Catalog no. sc-558, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) was added to equivalent protein amounts
of sample and incubated at 4°C for 1 h. Immune complexes were
then bound to protein A/G beads for 1 h at 4°C. Immuno-
precipitates were washed once in lysis buffer, twice in phosphate-
buffered saline (PBS) containing 1% Triton X-100 and twice in
PBS. Laemmli sample buffer was added and the samples were
boiled. Equal amounts of protein were separated in 7.5% sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). Proteins were blotted to polyvinylidene difluoride
(PVDF) membrane and probed with a-Ptyr4G10 antibody (Catalog
no. 05-321, Upstate Biotechnology, Inc., Lake Placid, NY, USA)
or with a-FAK antibody. These experiments were repeated three
times.
PTEN immunoprecipitates and protein blots
Infected cells were lysed in a buffer containing 10 mM Tris–HCl,
pH 8.0, 50 mM NaCl, 5 mM EDTA, 50 mM sodium fluoride (NaF),
1% NP-40, 1 mM Na3VO4, 1 mM PMSF. Anti-FLAG M2 beads
(Catalog no. A-1205, Sigma Chemical Co.) were added to lysates
and the mix was incubated for 2 h at 4°C. Immunoprecipitates
were washed 3 ´ with lysis buffer and once with Tris-buffered
saline (TBS)-0.03% Brij-35. Proteins were separated in 10% SDS-
PAGE and blotted to PVDF membrane. Blots were probed with 
a-PTEN antibody (Catalog no. 06-894, Upstate Biotechnology,
Inc.). The experiment was repeated twice.
FACs analysis
Cells were removed from tissue culture plastic with a room
temperature incubation with 10 mM EDTA in Hank’s balanced salt
solution, washed twice in PBS, then incubated with anti-integrin
a4 antibody (Catalog no. 12077-012, Gibco) or with anti-integrin
a5 antibody (Catalog no. CP12L, Oncogene Research Products,
Cambridge, MA, USA) for 1 h at 22°C. Cells were then washed
twice in PBS and incubated with a fluorescein isothiocyanate
(FITC)-conjugated secondary antibody for 1 h at 37°C. After two
washes in PBS, cells were fixed with 70% ethanol and subjected to
fluorescence activated cell sorting.
Invasion
Cells were suspended in 0.23% trypsin–EDTA (Catalog no.
15050–057, Gibco Life Technologies, Grand Island, NY) and
placed on SU-basement membranes with or without fetal calf
serum (FCS) according to established methods (Livant et al, 1995)
for 4 h at 37°C, the time required to observe maximal invasion
percentages for normal and metastatic cells (Livant et al, 1995,
and data not shown). The percentages of spread and adherent cells
were evaluated in each assay to check viability prior to fixation in
2% formaldehyde and scored at 400 ´ magnification using phase
contrast optics. Viability ranged from 90 to 98% in all assays.
Mean invasion percentages resulted from three independent deter-
minations involving the scoring of all cells in contact with the
invasion substrates. Fn-FCS was prepared by repeated affinity
chromatography of FCS on gelatin sepharose as previously
described (Catalog no. 17095601, Pharmacia Biotech, Piscataway,
NJ, USA) (Akiyama and Yamada, 1985). The pFn depletion was
confirmed by immunoblotting with a-Fn antibody (Catalog no.
12112–017, Gibco Life Technologies) (Hayman et al., 1982, data
not shown). LY294002 (Catalog no. L-9908, Sigma Chemical Co.)
stock solution was 25 mM in 100% ethanol. LY294002 was added
to fresh cell media to a final concentration of 25 mM for 24 h prior
to the start of the invasion assay. Ten microlitres of 100% ethanol
was added to an identical plate as a control.
RESULTS
ErbB-2 overexpression results in anchorage-
independent survival and growth of HME cells
In previous work, we developed a series of cell lines by retroviral
infection of the immortalized HME cell line, H16N2, with a vectorcontaining the full-length human ERBB-2 gene. We found that,
when selected for proliferation in serum-free, growth factor-free
medium, the transduced cells expressed very high levels of
p185ERBB-2 that were constitutively tyrosine phosphorylated.
Importantly, these cells expressed levels of activated p185ERBB-2
that are equivalent to levels expressed by HBC with an ERBB-2
gene amplification. Thus, as predicted from studies using ERBB-2
amplified HBC cells (Ram et al, 1996), high level ERBB-2 over-
expression and activation results in multiple growth factor 
independence (Woods Ignatoski et al, 1999).
To begin to examine other altered phenotypes that result from
ERBB-2 overexpression, H16N2 cells expressing different levels
of ERBB-2 protein (infected 1 ´ with pTPERBB2 or infected 3 ´
with pTPERBB2-infected) were tested for their ability to grow in
soft agar. Figure 1 demonstrates that, like breast cancer cells with
an ERBB-2 gene amplification, H16N2 cells overexpressing
ERBB-2 have the ability to survive under anchorage-independent
conditions. Furthermore, H16N2 cells expressing the highest
levels of p185ERBB-2 (3 ´ pTPERBB2-infected) grew to form large
colonies in agar. Thus, progressive overexpression of ERBB-2
resulted in increasing ability of HME cells to grow in an
anchorage-independent manner. These results are consistent with
those reported previously by Pierce et al (1991).
ERBB-2 overexpressing cells acquire invasive potential
To assess the invasive capacity of H16N2-ERBB2 cells, we used a
novel assay that utilizes naturally occurring sea urchin (SU)
embryo basement membranes. This experimental system allows
one to assess the invasive capacity of human cancer cells and
transformed cells in a completely defined system, because, as they
are obtained from an invertebrate, SU-basement membranes are
naturally serum-free. This technique has been described previ-
ously and accurately reflects the in vivo invasive and metastatic
capacity of a variety of cancer and normal cell types (Livant et al,
1995).
We first assessed the invasive capacity of human breast cancer
cell lines developed in our laboratory, and compared that to the
invasive capacity of H16N2-ERBB2 cells, and vector transduced
controls. Figure 2A shows that three human breast cancer cell
lines, all of which were derived from aggressive breast cancers,
but which have different molecular etiologies, expressed signifi-
cant invasive capacity in this system. By contrast, HME cells
failed to invade under these same conditions. H16N2-ERBB2 cells
exhibited invasive capacity similar to that expressed by breast
cancer cells, whereas control vector-transduced cells were not
invasive. These results indicate that high level overexpression of
p185ERBB-2 results in important transformed phenotypes beyond
growth factor independence and anchorage independent growth.
It was demonstrated previously that invasion of prostate cancer
cells through SU-basement membranes is dependent on the pres-
ence of plasma fibronectin, and that the PHSRN sequence of the
fibronectin cell-binding domain is sufficient to stimulate invasion
(DL Livant, manuscript submitted). The PHSRN sequence is a
known ligand for the a5b1 integrin (Aota et al, 1994). It has been
shown previously that a5b1 integrin binding to plasma fibronectin
fragments containing the cell-binding domain but not the C-
terminal domain, which contains the binding site for a4b1 integrin,
results in the activation of metalloproteinase gene expression in
fibroblasts which is essential for invasion (Huhtala et al, 1995).
We therefore examined the dependence on plasma fibronectin for
the invasion of breast cancer cells and H16N2-ERBB2 cells, as
well as their expression of a5b1 and a4b1 integrins. Figure 2B
shows that breast cancer cells and H16N2-ERBB2 cells were inva-
sive in the presence of serum, but not serum that had been specifi-
cally depleted of fibronectin. Similarly, cells were only invasive in
serum-free conditions when fibronectin was added to the medium.
To examine integrin expression in these cells, FACs analysis
was performed using the cell lines described above following
incubation of intact, non-fixed cells with fluorescently tagged anti-
bodies against the a4 and a5 integrins. Table 1 shows that breast
cancer cells express dramatically lower levels of cell surface a4
integrins than do normal HME cells, consistent with results
obtained previously with prostate epithelial and invasive prostate
cancer cells (Witkowski et al, 1993; Roklin and Cohen, 1995).
Similarly, control vector transduced H16N2 cells, which are non-
invasive, express a4; whereas, this integrin was down-regulated
from the cell surface in invasive H16N2-ERBB2 cells.
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Figure 1 Cells with ERBB-2 overexpression grow in an anchorage-
independent manner. Control cells (H16N2/PTP), HBC cell lines (SUM-
190PT, SUM-225CWN, and SkBr-3), and cells increasingly overexpressing
ERBB-2 (1 ´ and 3 ´) were plated in agar, grown for 2 weeks, stained with a
vital stain and photographedERBB-2 mediated invasion in HME cells 669
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Interestingly, a5 expression was increased in the invasive H16N2-
ERBB2 cells as compared to the vector transduced controls. These
results are consistent with the hypothesis that invasion by trans-
formed breast epithelial cells through naturally occurring base-
ment membranes is mediated by interactions between specific
integrins and particular domains of plasma fibronectin. Thus, like
invasive breast and prostate cancer cells, H16N2-ERBB2 cells
have reduced expression of cell surface a4b1 integrins, which bind
to a specific region of plasma fibronectin, and which may be func-
tionally relevant to their capacity to invade basement membranes.
Experiments are underway to evaluate the role of cell surface a4
integrin in the invasive behaviour of HME cells.
Signalling pathways mediating the invasive phenotype
in ERBB-2 overexpressing cells
We and others have shown previously that an important conse-
quence of ERBB-2 overexpression is a dramatic increase in the
level of activation of phosphatidylinositol 3¢ kinase (PI 3¢ kinase)
and its downstream signalling pathways (Fedi et al, 1994; Soltoff
et al, 1994; Ram and Ethier, 1996). Therefore, a series of experi-
ments were performed to assess the role of this pathway in the
invasive potential of H16N2-ERBB2 cells.
The tumour suppressor gene, PTEN, is a phosphatase that regu-
lates the activity of the PI 3¢-kinase pathway by virtue of its ability
to directly dephosphorylate PIP3 (Maehama and Dixon, 1998).
Therefore, we prepared retroviral expression vectors containing
full-length human PTEN, or a mutant PTEN that has the ability to
bind substrate but which is defective in both its lipid and protein
phosphatase activities. Figure 3A illustrates the constructs used,
and Figure 3B shows the expression of the transduced PTEN
proteins in H16N2-ERBB2 cells following infection with the
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Table 1 Cell surface integrin expressiona
Cell line a4 expressionb a5 expressionb
HME 54 62
SUM-149PT 0 10
SUM-190PT 14 27
H16N2-PTP 55 47
H16N2-ERBB-2 11 86
H16N2-ERBB2/PTENWT 12 21
aAs determined by FACs analysis. bPer cent increase in amount of staining
for a4 or a5 integrins over negative control.retroviral vectors. Next, basement membrane invasion experi-
ments were performed using H16N2-ERBB2 cells and PTEN-
infected versions of the same cells. Figure 3C shows that, whereas
H16N2-ERBB2 cells are invasive, overexpression of wild-type
PTEN completely abrogated their invasive capacity. Infection of
H16N2-ERBB2 cells with a vector containing the cs-PTEN
mutant reduced, but did not eliminate, the invasive capacity of the
cells. This result is consistent with the ability of the mutant protein
to bind and sequester substrate without dephosphorylating it,
which allows the mutant PTEN to partially block PIP3 signalling
(Maehama and Dixon, 1998).
To confirm that signalling from PI 3¢-kinase is important for
ERBB-2-induced invasion of basement membranes, H16N2-
ERBB2 cells and control cells were incubated with the PI 3¢-
kinase inhibitor LY294002 and tested for invasive capacity. Figure
4 shows that this compound, like PTEN, completely blocked the
invasive capacity of H16N2-ERBB2 cells.
Recently, Tamura et al (1999) demonstrated that PTEN blocks
the invasiveness of transformed cells by directly dephosphorylating
pp125FAK. However, the experiments of Maehama and Dixon
(1998) suggests that, under conditions that are relevant to the in
vivo situation, pp125FAK is a poor substrate for PTEN. Therefore,
we performed experiments to assess the pp125FAK protein activation
status in invasive H16N2-ERBB2 cells versus non-invasive control
cells, and to assess the role of PTEN in modulating pp125FAK
tyrosine phosphorylation in these cells.
To determine if the level of tyrosine phosphorylated pp125FAK
was elevated in invasive H16N2-ERBB2 cells compared to
controls, FAK immunoprecipitates were used to prepare Western
blots that were probed with phosphotyrosine antibodies. The data
in Figure 5A shows that overexpression of p185ERBB-2 in H16N2-
ERBB2 cells did not result in significant changes in the levels of
tyrosine phosphorylated pp125FAK. However, in these blots, we did
detect a tyrosine phosphorylated p185 that co-immunoprecipitated
with FAK in the ERBB-2 overexpressing cells, but not in control
cells. Reprobing of an identical blot with ERBB-2 specific anti-
bodies confirmed the identity of the tyrosine phosphorylated
protein as p185ERBB-2. The data in Figure 5A also shows that the
association of pp125FAK with p185ERBB-2, detected in the H16N2-
ERBB-2 cells, is also detectable in the SkBr-3 breast cancer cell
line which expresses high levels of p185ERBB-2 as a result of a gene
amplification. Thus, whereas levels of tyrosine phosphorylated
FAK are not altered in invasive ERBB-2 overexpressing cells,
p185ERBB-2 can be detected in immunocomplexes with pp125FAK
when ERBB-2 is expressed to high levels.
Experiments were next performed to examine the influence of
PTEN overexpression on levels of tyrosine phosphorylated
pp125FAK and its association with p185ERBB-2. The results shown in
Figure 5B indicate that PTEN overexpressing cells that have lost
their invasive capacity express the same levels of tyrosine phos-
phorylated pp125FAK as non-PTEN overexpressing cells with full
invasive capacity. Furthermore, PTEN expression did not influ-
ence the association of p185ERBB-2 with pp125FAK, and did not result
in the re-expression of a4 integrin on the cell surface (Fig. 5 and
670 KM Woods Ignatoski et al
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Figure 3 PI3¢ kinase is involved in the invasion of HBC and ERBB-2
overexpressing cells. (A) FLAG-tagged PTEN and PTEN CS (C124S) were
ligated into the biscistronic vector pTP2000. FL = FLAG Tag. (B) Western blot
on anti-FLAG immunoprecipitates using anti-FLAG antibody showing that
H16N2-ERBB-2/PTEN and H16N2-ERBB-2/PTEN CS were expressing
exogenous PTEN. Lanes: H16N2-PTP, 1; H16N2-ERBB-2, 2; H16N2-ERBB-
2/PTP, 3; H16N2-ERBB-2/PTEN, 4; H16N2-ERBB-2/PTEN CS, 5. 
(C) H16N2-ERBB-2/PTEN WT and H16N2-ERBB-2/PTEN CS cells were
used in invasion assays. Columns: H16N2-PTP, 1; H16N2-ERBB-2, 2;
H16N2-ERBB-2/PTP, 3; H16N2-ERBB-2/PTEN, 4; H16N2-ERBB-2/PTEN
CS, 5. Per cent invasion relative to H16N2-ERBB-2 invasion was graphed
Figure 4 The PI 3¢-kinase inhibitor, LY294002, blocks invasion of HBC and
ERBB-2 overexpressing cells. HBC cells and H16N2-ERBB-2 cells were
incubated with LY294002 then tested for invasion. Per cent invasion relative
to SUM-149PT invasion givenTable 1). These results, coupled with the data obtained from the
experiments using LY294002, suggest that the ability of PTEN to
block invasion of H16N2-ERBB2 cells is related to its ability to
block PI 3¢-kinase signalling rather than to its ability to directly
dephosphorylate pp125FAK. Indeed, our results are consistent with
the previous observations (Maehama and Dixon, 1998) which
indicate that under physiological conditions, PTEN does not
dephosphorylate pp125FAK. This finding raises the possibility that
the interaction of p185ERBB-2 with pp125FAK in ERBB-2 over-
expressing cells can alter the expression or cellular localization of
a4b1 integrins. Further work will be required to dissect the roles of
ERBB-2, PI 3¢-kinase, and pp125FAK in the invasive potential of
ERBB-2 overexpressing breast epithelial cells.
Taken together, the data obtained in these studies demonstrate
that high-level overexpression of activated p185ERBB-2 results in the
acquisition of altered phenotypes typically expressed by aggres-
sive cancer cells. ERBB-2 overexpressing cells are not only
growth factor-independent and anchorage independent for growth,
these cells can invade naturally occurring basement membranes in
a pFn-dependent manner. When expressed to very high levels,
p185ERBB-2 can be detected in immunocomplexes with pp125FAK,
and blocking PI 3¢-kinase signalling in these cells completely
abrogates the invasive potential of H16N2-ERBB2 cells.
DISCUSSION
ERBB-2 is an important oncogene in breast and other cancers, and
overexpression and constitutive activation of its tyrosine kinase is
essential to its oncogenic properties (DiFiore et al, 1987, 1990a,
1990b; Hudziak et al, 1987; Lonardo et al, 1990; Pierce et al,
1991). Despite the clear role of ERBB-2 in the aetiology of some
human cancers, the specific cellular phenotypes expressed by
cancer cells that are the direct result of ERBB-2 overexpression
have not been completely defined.
In previous work, we demonstrated that breast cancer cells that
overexpress p185ERBB-2 are independent of growth factors required
by normal HME cells for continuous proliferation in serum-free
medium (Ram et al, 1996). More recently, we showed that over-
expression of p185ERBB-2 in HME cells to levels expressed by
breast cancer cells with a ERBB-2 gene amplification is sufficient
to induce the growth factor independence phenotype (Woods
Ignatoski et al, 1999). The activation of signalling pathways, such
as PI 3¢-kinase and MAP kinase, in ERBB-2 overexpressing cells
has been reported by a number of investigators and is consistent
with the ability of the ERBB-2 kinase to stimulate growth of
cancer cells (Benlevy et al, 1994; Marte et al, 1995). However,
HBC cells exhibit other altered cellular phenotypes beyond growth
factor independence. Therefore, we undertook experiments to
determine if ERBB-2 overexpression in HME cells could induce
other altered cellular phenotypes expressed by breast cancer cells.
H16N2 human mammary epithelial cells are a keratin-19-posi-
tive cell line that was immortalized by transduction of the entire
HPV-16 genome (Band and Sager, 1989; Band et al, 1990). These
cells are immortal in culture, are partially independent of insulin
for growth in serum-free medium, but are still completely depen-
dent on EGF for growth. In addition, H16N2 cells do not grow in
soft agar, are not invasive in vitro, and do not form tumours in
immunodeficient animals. H16N2-ERBB2 cells, which express
levels of activated ERBB-2 equivalent to HBC cells with a ERBB-
2 gene amplification, are independent of both insulin and EGF for
growth in serum-free medium, have the ability to grow under
anchorage-independent conditions, and can invade naturally
occurring basement membranes. Thus, this is the first report to
demonstrate that ERBB-2 overexpression can have a direct effect
on the invasive potential of HME cells, and that progressive
ERBB-2 overexpression results in the acquisition of phenotypes
associated with increasing malignancy.
Based on the findings of our study, there are at least two path-
ways that are affected by overexpression of ERBB-2 which are
important to the invasive potential of the cells. The first is the
ERBB-2-mediated activation of PI 3¢ kinase signalling. The
second is the plasma fibronectin dependence for the invasive
phenotype, and the related down-regulation of cell surface a4 inte-
grin in the invasive cells.
Several laboratories, including our own, have demonstrated that
overexpression of ERBB-2 results in high level activation of PI 3¢
ERBB-2 mediated invasion in HME cells 671
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Figure 5 ERBB-2 co-immunoprecipitates with FAK in H16N2-ERBB-2 cells.
(A) Anti-FAK immunoprecipitates from control and ERBB-2 overexpressing
cells probed with anti-PTYR4G10. FAK and ERBB-2 are indicated; an identical
blot was probed with anti-ERBB-2 to ensure that the tyrosine-phosphorylated
p185 was ERBB-2. Anti-FAK immunoprecipitates from H16N2-ERBB-2 and
SkBr-3 cells were also probed with anti-PTYR4G10 to show co-
immunoprecipitating tyrosine-phosphorylated p185. (B) FAK is not
dephosphorylated in PTEN-expressing cells. Anti-FAK immunoprecipitations
from H16N2-ERBB-2 (Lane 1), H16N2-ERBB-2/PTP (Lane 2), H16N2-ERBB-
2/PTEN WT (Lane 3), or H16N2-ERBB-2/PTEN CS (Lane 4) cells were
probed with anti-PTYR4G10; an identical blot was probed with anti-FAK to
show FAK levelskinase (Fedi et al, 1994; Soltoff et al, 1994; Ram and Ethier, 1996).
There are at least three possible mechanisms by which ERBB-2
modulates the activity of this pathway (reviewed in Earp et al,
1986; Alroy and Yarden, 1997). First, the cytoplasmic domain of
p185ERBB-2 has a single YXXM binding site for the regulatory
subunit of PI 3¢ kinase. Thus, either direct or indirect phoshoryla-
tion of this tyrosine residue can result in activation of the enzyme.
Second, ERBB-2 activation often results in the concomitant acti-
vation of ERBB-3, which has six YXXM sites in its cytoplasmic
domain. Thus, ERBB-3 is a potent activator of PI 3¢ kinase, and
the H16N2-ERBB2 cells used in these studies express high levels
of constitutively tyrosine phosphorylated ERBB-3. The third
potential mechanism involves the association of the p85 subunit of
PI 3¢ kinase with tyrosine phosphorylated pp125FAK (Bachelot et al,
1996). This mechanism is potentially significant in our experi-
ments since, in invasive ERBB-2 overexpressing cells, p185ERBB-2
was found to be associated with activated pp125FAK in immuno-
complexes, and the p85 subunit of PI 3¢ kinase was detectable in
the same immunocomplexes (not shown). Thus, it is possible that
the association of p185ERBB-2 with pp125FAK could potentiate PI 3¢
kinase activation beyond what occurs as a result of ERBB-2
homodimer and ERBB-2/ERBB-3 heterodimer interactions. The
data obtained in our studies indicate that PI 3¢ kinase activation is
a direct mediator of the invasive phenotype in that both LY294002
and exogenous expression of PTEN reversed the invasive capacity
of H16N2-ERBB2 cells. The effect of PTEN is particularly inter-
esting in that PTEN transduced cells proliferate as well in mono-
layer culture as control cells (data not shown). In contrast, the cells
are growth inhibited by the concentration of LY204002 used to
block invasion (data not shown).
The SU-basment membrane invasion assay used in these studies
offers the ability to study cell invasion of naturally occurring base-
ment membranes under serum-optional conditions. The defined
nature of the assay allowed for the previous observation of the
importance of plasma fibronectin for invasion of basement
membranes by prostate cancer cells (Livant et al, 1995), and for
the observation of its importance for basement membrane invasion
by breast cancer cells, as described here. Like metastatic breast
and prostate cancer cells, H16N2-ERBB2 cells also only invaded
SU-basment membranes in the presence of plasma fibronectin.
The importance of plasma fibronectin for invasion is particularly
interesting because all cells examined thus far that are invasive in
this assay have been found to express low levels of cell surface a4
integrin, while expressing high levels of a5. Indeed, cell surface a4
integrin expression, which is normal in H16N2 cells, was found to
be down-regulated in ERBB-2 overexpressing cells with invasive
potential. The down-regulation of a4 detected by FACs analysis
was not observed in Western blots (not shown) suggesting that
integrin trafficking is altered in the invasive cells. These results are
consistent with those recently reported by Weaver et al (1997) who
not only demonstrated that the repertoire of integrin expression is
functionally important to the transformed phenotype of the cells,
but that changes in cell-surface localization of integrins can occur
without changes in overall levels of transcription or translation.
Our data are also consistent with those of Seftor et al (1998) who
demonstrated that maspin, which can modulate the invasive
capacity of MDA-435 cells, can directly modulate cell surface
expression of a number of integrins.
The loss of cell surface a4b1 integrin in the presence of a5b1 is
important because each of these integrin dimers bind to distinct
domains of plasma fibronectin. In normal cells, the cell binding
domain of pFn interacts with a5b1, whereas the C-terminal domain
interacts with a4b1 integrin. This dual interaction is important for
the maintenance of normal cells in a non-motile, non-invasive
state (Postlethwaite et al, 1981; Seppa et al, 1981; Clark et al,
1988). During wound healing, plasma fibronectin fragments are
generated by proteolysis resulting in the formation of fragments
containing the cell-binding domain. These fragments contain the
PHSRN sequence, but do not contain the C-terminal domain that
binds a4b1 integrin. The stimulation of fibroblasts by proteolytic
fragments of plasma fibronectin is essential for the invasion and
migration of cells during this process (Grinnell et al, 1992).
Indeed, Huhtala et al (1995), demonstrated that in fibroblasts,
interaction of a5b1 with pFn in the absence of a4b1, results in the
up-regulation of metalloproteinases that are important for invasion
across basement membranes. Similarly, Livant et al (submitted for
publication) demonstrated that direct stimulation of a5b1 integrin
using the PHSRN peptide derived from the pFn cell-binding
domain, was sufficient to induce migration and invasion by normal
epithelial cells. Thus, down-regulation of cell surface a4 integrin
(and the consequent loss of a4b1 plasma fibronectin receptors) in
ERBB-2 overexpressing cells, as well as in breast and prostate
cancer cells, is likely to be of functional significance to their
ability to invade basement membranes and to metastasize.
Since integrins are involved in motility and invasion of cancer
cells, and since integrin signalling is known to be mediated by
activation of pp125FAK (Guan, 1997; Ilic et al, 1997), the observa-
tion that p185ERBB-2 and pp125FAK interact and can be co-immuno-
precipitated in invasive, ERBB-2 overexpressing cells, is
particularly intriguing. This result suggests the possibility that the
interaction of p185ERBB-2 and pp125FAK, and the down-regulation of
a4b1 integrin from the cell surface, are functionally related. In
addition, since the p85 subunit of PI 3¢ kinase is also detectable in
pp125FAK immunoprecipitates, and blocking PI 3¢ kinase signalling
abrogates invasiveness of the cells, the interaction of p185ERBB-2
and pp125FAK could be important for the overall activation of PI 3¢-
kinase signalling. Distinguishing the precise roles of p185ERBB-2,
pp125FAK, PI 3¢ kinase activation, and cell surface a4b1 integrin
expression in mediating the invasive phenotype will require
further experiments.
In summary, the data reported here, and previously, indicate that
progressive overexpression of ERBB-2 in HME cells results in the
step-wise acquisition of malignant properties. Moderate ERBB-2
overexpression is sufficient to liberate cells from their require-
ments of exogenous insulin-like growth factors for proliferation,
but is not sufficient to drive EGF independence, growth in soft-
agar, or invasive capacity. However, expression of ERBB-2 to
levels seen in breast cancer cells with a gene amplification not
only results in complete growth factor autonomy, but also yields
cells with robust anchorage-independent growth potential and with
the ability to invade naturally occurring basement membranes.
HME cells expressing high levels of p185ERBB-2 exhibit many alter-
ations in normal signalling patterns including; constitutive tyro-
sine phosphorylation of ERBB-2, ERBB-3 and EGFR, constitutive
activation of PI 3¢ kinase, association of ERBB-2 with pp125FAK,
and down-regulation of cell surface a4b1 integrins. Future studies
will be aimed at dissecting the relative contributions of each of
these signalling pathways in mediating the different altered pheno-
types exhibited by ERBB-2 overexpressing mammary epithelial
cells and breast cancer cells.
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